tofacitinib / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 70 Diseases   129 Trials   129 Trials   8945 News 


12345678910111213...120121»
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China. (Pubmed Central) -  Nov 18, 2024   
    The ICER was 7,880.38 yuan/QALY, which is well below the WTP threshold of 1.5 times China's GDP per capita, indicating favorable cost-effectiveness. In the context of China's healthcare system, Upadacitinib represents a cost-effective long-term first-line treatment option for moderate-to-severe RA patients.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Review, Journal:  JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases. (Pubmed Central) -  Nov 18, 2024   
    They have also shown promising results in clinical trials for the treatment of other autoimmune conditions. We present here their mechanisms of action, and the main data about JAKi use on systemic and autoimmune diseases.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly
    Journal:  JAK inhibitors in refractory dermatomyositis: A case series. (Pubmed Central) -  Nov 13, 2024   
    Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    New P4 trial:  JAK-TAP: JAK Inhibitor Dose TAPering Strategy Study (clinicaltrials.gov) -  Nov 13, 2024   
    P4,  N=308, Not yet recruiting, 
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
    The use of JAK inhibitors in difficult-to-treat adult-onset Still's disease () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_59;    
    Tocilizumab was discontinued in January 2023 due to inefficacy, and anakinra was initiated...Future research should focus on elucidating the optimal dosing and duration of JAK inhibitor therapy in patients with refractory AOSD. Additionally, long-term follow-up studies are essential to fully understand the safety profile of these agents.Key learning points:
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
    The role of JAK inhibitors in difficult-to-treat adult-onset Still's disease: a case series () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_57;    
    Initial treatment with 60 mg oral prednisolone showed some response, but polyarthritis necessitated further intervention...Colchicine was tried next...The successful outcomes with JAK inhibitors highlight their ability to achieve disease control where other treatments failed, demonstrating their efficacy in reducing systemic inflammation and disease activity.Further research is warranted to establish optimal dosing, duration of therapy, and long-term safety profiles of JAK inhibitors in this patient population. These preliminary results are encouraging and suggest a new avenue for treating AOSD.Key learning points:
  • ||||||||||  A complex case of psoriatic juvenile idiopathic arthritis () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_40;    
    These preliminary results are encouraging and suggest a new avenue for treating AOSD.Key learning points: She is ANA negative and RF negative.She was initially treated with intravenous methylprednisolone (IVMP), methotrexate and joint injections...September/2018S/c methotrexatePolyarthritisJanuary/2019S/c adalimumabInadequate response to MethotrexateMarch/2020S/c Methotrextae S/c adalimumabConcerns about compliance-change to IV medicationsApril/2020IV methotrexateIV infliximab 4mg/kgFebruary/2021IV infliximab increased to 6mg/kgInadequate responseMay/2021IV infliximab increased to 8mg/kgInadequate responseDecember/2021IV infliximabInadequate response to infliximab-escalateJanuary/2022IV tocilizumabDecember/2022IV methotrexateIntoleranceMarch/2023IV tocilizumabInadequate response to tocilizumab-escalateApril/2023IV abataceptJune/2023Oral methotrexateAdded as adjunct to AbataceptDecember/2023IV abatacept Oral methotrexateInadequate response to Abatacept-escalate Intolerence to methotrexateJanuary/2024Oral tofacitinibJune/2024S/c adalimumabInadequate response to tofacitinib aloneOA23 Table 1...Other differential diagnoses were considered and ruled out.
  • ||||||||||  Are we in sight of disease control  () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_39;    
    We trialled Infliximab infusions for three months alongside Methotrexate but a lack of response made us switch back to Tocilizumab.Despite regular treatment, she continued to have multiple flares needing steroids. We swapped Tocilizumab to Abatacept infusions alongside Methotrexate...We commenced her on Tofacitinib with Anakinra, and in the last two months we have swapped Anakinra back to Tocilizumab infusions as the monthly flares persisted.The patient and family were kept informed of the management plans throughout this period...The question is should we be escalating to BMT just yet, or is there something else we could do to achieve optimal disease control in this young person.Key learning points:
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    Upadacitinib exposure during pregnancy in seronegative Rheumatoid arthritis () -  Nov 8, 2024 - Abstract #BSRCBC2024BSR_CBC_12;    
    We swapped Tocilizumab to Abatacept infusions alongside Methotrexate...We commenced her on Tofacitinib with Anakinra, and in the last two months we have swapped Anakinra back to Tocilizumab infusions as the monthly flares persisted.The patient and family were kept informed of the management plans throughout this period...The question is should we be escalating to BMT just yet, or is there something else we could do to achieve optimal disease control in this young person.Key learning points: She has no history of spontaneous abortions.At the time of her RA diagnosis, the patient was considering pregnancy and was initially started on sulfasalazine...Despite this treatment, she exhibited only a partial response with ongoing disease activity, leading to a change to etanercept in August 2021.When etanercept proved ineffective, adalimumab was considered in January 2022...She was subsequently started on certolizumab...Access to a medical obstetrician team is invaluable in managing such cases.
  • ||||||||||  tofacitinib / Generic mfg.
    Clinical, Retrospective data, Journal:  Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial. (Pubmed Central) -  Nov 6, 2024   
    P3
    She has no history of spontaneous abortions.At the time of her RA diagnosis, the patient was considering pregnancy and was initially started on sulfasalazine...Despite this treatment, she exhibited only a partial response with ongoing disease activity, leading to a change to etanercept in August 2021.When etanercept proved ineffective, adalimumab was considered in January 2022...She was subsequently started on certolizumab...Access to a medical obstetrician team is invaluable in managing such cases. In patients with COVID-19 pneumonia, the use of tofacitinib compared to placebo did not result in clinically meaningful changes in blood counts or liver enzymes over the first 7 days after randomization.
  • ||||||||||  In Vitro Drug Profiling to Guide Treatment for Relapse/Refractory AML (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_4284;    
    Importantly, in vitro drug sensitivities of AML samples were correlated with in vivo anti-leukaemia effect in respective patient-derived xenogarafts e.g. entrectinib, venetoclax, alectinib and ponatinib in combination with azacitidine...Conclusions A biologically meaningful and clinically relevant in vitro drug screening platform with high throughput capacity and short turnover time showed potential of clinical application to guide treatment in relapse/refractory AML at real-time. It also provided insights to the development of novel therapeutic targets in certain AML subtypes.
  • ||||||||||  Different Effects of Selective Janus Kinase (JAK) Inhibitors in Murine Bone Marrow Failure (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_3536;    
    Our results support the hypothesis that combined JAK1 and JAK2 blockade is essential to ameliorate the immune environment in BMF, whereas strong JAK3 combined with weak JAK1/2 inhibition (TOF), and very selective JAK1 (SOL) or JAK2 (FED) blockade, were inferior. None of the tested JAKi had apparent hematological toxicity.
  • ||||||||||  Bimzelx (bimekizumab-bkzx) / UCB
    Cost-Effectiveness Analysis of Bimekizumab in Patients With Active Psoriatic Arthritis (PSA) in Greece () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2791;    
    As only TNFi-experienced patients were included in the analysis, secukinumab 300mg was used to reflect its licensed posology. The analysis suggests that the additional therapeutic benefits of bimekizumab makes it a cost-efficient treatment option, in Greece, despite its incrementally higher costs.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Tyenne (tocilizumab-aazg) / Fresenius Kabi, Rituxan (rituximab) / Roche
    Rheumatoid Arthritis, Cost-Effectiveness Analysis of Biosimilar Tocilizumab in Spain () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1865;    
    The model included abatacept, biosimilar adalimumab, baricitinib, certolizumab, etanercept, filgotinib, golimumab, infliximab, rituximab, sarilumab, reference and biosimilar tocilizumab, tofacitinib, and upadacitinib... Biosimilar tocilizumab has proven to be a cost-effective alternative for the treatment of rheumatoid arthritis patients, even against the least expensive available biological or targeted synthetic DMARD comparator in Spain in a lifetime-horizon perspective.
  • ||||||||||  Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Cost-Effectiveness Analysis of Filgotinib Versus Tofacitinib As First-Line Treatments for Rheumatoid Arthritis in Greece () -  Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_59;    
    Filgotinib is cost-effective and dominates over tofacitinib in the Greek healthcare environment, providing comparable clinical outcomes with significant cost savings for the third-party payer. This analysis supports the adoption of filgotinib as a preferred treatment strategy for RA, emphasizing its value in combining clinical efficacy with economic efficiency.
  • ||||||||||  tofacitinib / Generic mfg.
    Retrospective data, Journal:  Tofacitinib for ulcerative colitis: A promising treatment option. (Pubmed Central) -  Nov 4, 2024   
    This study has clinical reference value but also has some limitations. Previous studies, including this clinical trial, have shown that tofacitinib could be a promising treatment option for UC, but further clinical research is required to prove this point.
  • ||||||||||  tofacitinib / Generic mfg.
    Journal:  Tofacitinib-Associated Demyelination and Bullous Pemphigoid. (Pubmed Central) -  Oct 28, 2024   
    In addition, tofacitinib alleviated salivary gland inflammation and hypofunction, offering new insights into the clinical management of SjD. No abstract available